BAFNAPHARM - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

Bafna Pharmaceuticals Ltd board approves rights issue #BafnaPharmaceuticalsLimited #INE878I01022 #BAFNAPH #FundRaising #RightsIssue

BAFNAPHARM - Announcement under Regulation 30 (LODR)-Raising of Funds

BAFNAPHARM - Update on board meeting

BAFNAPHARM - Board Meeting Intimation for Quarterly Results And General

BAFNAPHARM - Statement Of Investor Complaints For The Quarter Ended September 2021

BAFNAPHARM - Shareholding for the Period Ended September 30, 2021

BAFNAPHARM - Board Meeting Outcome for Outcome Of Board Meeting Held On 16Th Sep 2021

BAFNAPHARM - Board Meeting Intimation for Proposal Of Availing Working Capital / Term Loan Facility For Expansion Program

BAFNAPHARM - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

BAFNAPHARM - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

BAFNAPHARM - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Bafna Pharma Posts INR 208.70 Lakhs Profit in Q1 #BafnaPharma

BAFNAPHARM - Q1 2021-22 Results

Bafna Pharmaceuticals Ltd Q1FY22 PAT slips QoQ to Rs. 2.08 crore #BafnaPharmaceuticals #Q1FY22 #ResultUpdate

BAFNAPHARM - Board Meeting Outcome for Outcome Of The Board Meeting Held On 05Th August 2021

BAFNAPHARM - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Inter-Alia Consider And Approve The Un-Audited #Part1